Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent
Not Applicable
Completed
- Conditions
- Malignant NeoplasmsBiliary Stricture
- Interventions
- Device: Biliary stent
- Registration Number
- NCT01512563
- Lead Sponsor
- Taewoong Medical Co., Ltd.
- Brief Summary
Paclitaxel covered metal biliary stent extents their patency rate comparing to the Common Covered Metallic Biliary Stent.
- Detailed Description
Paclitaxel covered metal biliary stent(Mira-Cover Biliary Stent) extents their patency rate comparing to the Common Covered Metallic Biliary Stent(Niti-S Biliary Stent.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 106
Inclusion Criteria
- Patient who is inoperable and/or unresectable cases of pancreatic cancer and/or biliary cancer with mid or distal CBD invasion
- Among patient of a.,Patient who previously had surgical biliary drainage of plastic stent have eligibility
Exclusion Criteria
- Patient who have life expectancy under 3 months
- Patient who have severe metastasis of Liver or whole body
- Patient who previously had surgical biliary drainage
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Paclitaxel ElutingCovered Metal Stent Biliary stent - Covered Metal Stent Biliary stent -
- Primary Outcome Measures
Name Time Method Accumulative Patency Rate 6 month
- Secondary Outcome Measures
Name Time Method Complications 6 months Accumulative Survival Rate 6 months Possibility of Other Treatment after Obstruction 6 months
Trial Locations
- Locations (3)
Soon Chun Hyang University Hospital Cheonan
🇰🇷Cheonan, Korea, Republic of
Catholic University of Daegu School of Medicine
🇰🇷Daegu, Korea, Republic of
Kangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of